CoChat

A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides

Ratishvili, Tamar, Quach, Huy Quang, Haralambieva, Iana H., Suryawanshi, Yogesh R., Ovsyannikova, Inna G., Kennedy, Richard B., Poland, Gregory A. · 2024 · Vaccine
Cited by 6

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2023.12.024

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 57

  1. Wang, 2022, Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5, Nature, 608, 603, 10.1038/s41586-022-05053-w · DOI · Paper page
  2. Nemet, 2022, Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection, N Engl J Med, 386, 492, 10.1056/NEJMc2119358 · DOI · Paper page
  3. McLean, 2022, The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 Vaccines, mBio, 13, 10.1128/mbio.02979-21 · DOI · Paper page
  4. Kurhade, 2022, Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster, Nat Med
  5. Wang, 2023, Antibody Response to Omicron BA.4-BA.5 Bivalent Booster, N Engl J Med, 388, 567, 10.1056/NEJMc2213907 · DOI · Paper page
  6. Poland, 2021, The need for broadly protective COVID-19 vaccines: beyond S-only approaches, Vaccine, 39, 4239, 10.1016/j.vaccine.2021.06.028 · DOI
  7. Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, e8
  8. Perez-Alos, 2022, Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors, Nat Commun, 13, 1614, 10.1038/s41467-022-29225-4 · DOI · Paper page
  9. Sette, 2023, T cell responses to SARS-CoV-2, Annu Rev Immunol, 41, 343, 10.1146/annurev-immunol-101721-061120 · DOI · Paper page
  10. Tarke, 2022, Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors, Int J Mol Sci, 23, 10.3390/ijms23137155 · DOI
  11. Moss, 2022, The T cell immune response against SARS-CoV-2, Nat Immunol, 23, 186, 10.1038/s41590-021-01122-w · DOI · Paper page
  12. Ferretti, 2020, Unbiased Screens Show CD8(+) T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein, Immunity, 53, 1095, 10.1016/j.immuni.2020.10.006 · DOI · Paper page
  13. Keeton, 2022, T cell responses to SARS-CoV-2 spike cross-recognize Omicron, Nature, 603, 488, 10.1038/s41586-022-04460-3 · DOI · Paper page
  14. GeurtsvanKessel, 202272202, Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients, Sci Immunol
  15. Yu, 2023, The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development, Emerg Microbes Infect, 12, e2164219, 10.1080/22221751.2022.2164219 · DOI
  16. Yan, 2022, Structural biology of SARS-CoV-2: open the door for novel therapies, Signal Transduct Target Ther, 7, 26, 10.1038/s41392-022-00884-5 · DOI · Paper page
  17. Jahirul Islam, 2023, A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites, Immunobiology, 228, 10.1016/j.imbio.2022.152302 · DOI
  18. Zandi, 2022, The role of SARS-CoV-2 accessory proteins in immune evasion, Biomed Pharmacother, 156, 10.1016/j.biopha.2022.113889 · DOI
  19. Bello-Perez, 2023, SARS-CoV-2 ORF8 accessory protein is a virulence factor, mBio., 14, 10.1128/mbio.00451-23 · DOI
  20. Ovsyannikova, 2004, Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides, J Virol, 78, 42, 10.1128/JVI.78.1.42-51.2004 · doi:10.1128/jvi.78.1.42-51.2004
  21. Johnson, 2009, Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development, Vaccine, 28, 38, 10.1016/j.vaccine.2009.09.126 · DOI
  22. Crooke, 2021, Identification of naturally processed Zika virus peptides by mass spectrometry and validation of memory T cell recall responses in Zika convalescent subjects, PLoS One, 16, e0252198, 10.1371/journal.pone.0252198 · DOI
  23. Quach, 2022, Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine, Sci Rep, 12, 15401, 10.1038/s41598-022-19679-3 · DOI
  24. Crooke, 2020, Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome, Sci Rep, 10, 14179, 10.1038/s41598-020-70864-8 · DOI
  25. Chu, 2020, Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study, Lancet Microbe, 1, e14, 10.1016/S2666-5247(20)30004-5 · DOI · Paper page
  26. Chang, 2022, A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the Delta and Omicron variants, Viruses, 14, 10.3390/v14071369 · DOI
  27. Estrella, 2011, A novel in vitro human macrophage model to study the persistence of mycobacterium tuberculosis using Vitamin D(3) and retinoic acid activated THP-1 macrophages, Front Microbiol, 2, 67, 10.3389/fmicb.2011.00067 · DOI
  28. UniProt, 2021, UniProt: the universal protein knowledgebase in 2021, Nucleic Acids Res, 49, D480, 10.1093/nar/gkaa1100 · DOI · Paper page
  29. Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res, 48, W449, 10.1093/nar/gkaa379 · DOI · Paper page
  30. Reynisson, 2020, Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data, J Proteome Res, 19, 2304, 10.1021/acs.jproteome.9b00874 · DOI · Paper page
  31. Nielsen, 2016, NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets, Genome Med, 8, 33, 10.1186/s13073-016-0288-x · DOI · Paper page
  32. Knierman, 2020, The human leukocyte antigen class II immunopeptidome of the SARS-CoV-2 spike glycoprotein, Cell Rep, 33, 10.1016/j.celrep.2020.108454 · DOI · Paper page
  33. Vita, 2019, The Immune Epitope Database (IEDB): 2018 update, Nucleic Acids Res, 47, D339, 10.1093/nar/gky1006 · DOI · Paper page
  34. Bui, 2006, Predicting population coverage of T-cell epitope-based diagnostics and vaccines, BMC Bioinf, 7, 153, 10.1186/1471-2105-7-153 · DOI · Paper page
  35. Khare, 2021, GISAID's Role in Pandemic Response, China CDC Wkly, 3, 1049, 10.46234/ccdcw2021.255 · DOI · Paper page
  36. Clark, 2016, GenBank, Nucleic Acids Res, 44, D67, 10.1093/nar/gkv1276 · DOI · Paper page
  37. Pickett, 2012, Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community, Viruses, 4, 3209, 10.3390/v4113209 · DOI · Paper page
  38. Sievers, 2011, Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega, Mol Syst Biol, 7, 539, 10.1038/msb.2011.75 · DOI · Paper page
  39. Bui, 2007, Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines, BMC Bioinf, 8, 361, 10.1186/1471-2105-8-361 · DOI · Paper page
  40. Mannar, 2022, SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization, Nat Commun, 13, 4696, 10.1038/s41467-022-32262-8 · DOI
  41. Pan, 2021, Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs, Proc Natl Acad Sci U S A, 118, 10.1073/pnas.2111815118 · DOI · Paper page
  42. Lee, 2020, Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells, Emerg Microbes Infect, 9, 2169, 10.1080/22221751.2020.1827985 · DOI
  43. Nagler, 2021, Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics, Cell Rep, 35, 10.1016/j.celrep.2021.109305 · DOI · Paper page
  44. Stanifer, 2020, Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells, Cell Rep, 32, 10.1016/j.celrep.2020.107863 · DOI · Paper page
  45. Zupin, 2022, Effect of short time of SARS-CoV-2 infection in Caco-2 cells, Viruses, 14, 10.3390/v14040704 · DOI
  46. Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol Cell Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI · Paper page
  47. Grifoni, 2020, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell, 181, e15
  48. Le Bert, 2020, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Nature, 584, 457, 10.1038/s41586-020-2550-z · DOI · Paper page
  49. Prakash, 2021, Genome-Wide B Cell, CD4(+), and CD8(+) T cell epitopes that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines, J Immunol, 206, 2566, 10.4049/jimmunol.2001438 · DOI · Paper page
  50. Meyers, 2021, Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation, npj Vaccines, 6, 71, 10.1038/s41541-021-00331-6 · DOI
  51. Tada, 2023, Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model, JCI Insight, 8, 10.1172/jci.insight.167306 · DOI
  52. Pardieck, 2022, A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection, Nat Commun, 13, 3966, 10.1038/s41467-022-31721-6 · DOI
  53. Heitmann, 2022, A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity, Nature, 601, 617, 10.1038/s41586-021-04232-5 · DOI · Paper page
  54. Li, 2014, Peptide vaccine: progress and challenges, Vaccines (Basel), 2, 515, 10.3390/vaccines2030515 · DOI · Paper page
  55. Obermair, 2022, High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape, Sci Adv, 8, 10.1126/sciadv.abl5394 · DOI
  56. Matchett, 2021, Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity, J Immunol, 207, 376, 10.4049/jimmunol.2100421 · DOI · Paper page
  57. Jing, 2022, T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components, JCI Insight, 7, 10.1172/jci.insight.158126 · DOI

Cited by

See all 6

Metadata

Authors
Ratishvili, T., Quach, H. Q., Haralambieva, I. H., Suryawanshi, Y. R., Ovsyannikova, I. G., Kennedy, R. B., & Poland, G. A.
Venue
Vaccine
Publisher
Elsevier BV
Published
2024-01
Volume
42
Issue
2
Pages
162-174
ISSN
0264-410X
Cited by
6
References
15
Language
en
Funders
  • Mayo Clinic
  • ICW Healthcare Ventures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides. https://app.cochat.ai/papers/10.1016/j.vaccine.2023.12.024
The paper
Ratishvili, T., Quach, H. Q., Haralambieva, I. H., Suryawanshi, Y. R., Ovsyannikova, I. G., Kennedy, R. B., & Poland, G. A. (2024). A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides. Vaccine. https://doi.org/10.1016/j.vaccine.2023.12.024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.